Literature DB >> 16421371

Restoring airway surface liquid in cystic fibrosis.

Felix Ratjen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16421371     DOI： 10.1056/NEJMe058293

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  11 in total

1.  Identification of the SPLUNC1 ENaC-inhibitory domain yields novel strategies to treat sodium hyperabsorption in cystic fibrosis airway epithelial cultures.

Authors:  Carey A Hobbs; Maxime G Blanchard; Omar Alijevic; Chong Da Tan; Stephan Kellenberger; Sompop Bencharit; Rui Cao; Mehmet Kesimer; William G Walton; Ashley G Henderson; Matthew R Redinbo; M Jackson Stutts; Robert Tarran
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-10-11       Impact factor: 5.464

Review 2.  Inhaled therapeutics for prevention and treatment of pneumonia.

Authors:  Amar Safdar; Samuel A Shelburne; Scott E Evans; Burton F Dickey
Journal:  Expert Opin Drug Saf       Date:  2009-07       Impact factor: 4.250

3.  Airway surface liquid depth measured in ex vivo fragments of pig and human trachea: dependence on Na+ and Cl- channel function.

Authors:  Yuanlin Song; Wan Namkung; Dennis W Nielson; Jae-Woo Lee; Walter E Finkbeiner; A S Verkman
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-10-09       Impact factor: 5.464

Review 4.  Diagnosis of cystic fibrosis.

Authors:  Karen Z Voter; Clement L Ren
Journal:  Clin Rev Allergy Immunol       Date:  2008-12       Impact factor: 8.667

5.  Identification of SPLUNC1's ENaC-inhibitory domain yields novel strategies to treat sodium hyperabsorption in cystic fibrosis airways.

Authors:  Carey A Hobbs; Maxime G Blanchard; Stephan Kellenberger; Sompop Bencharit; Rui Cao; Mehmet Kesimer; William G Walton; Matthew R Redinbo; M Jackson Stutts; Robert Tarran
Journal:  FASEB J       Date:  2012-07-13       Impact factor: 5.191

6.  Draft Genome Sequences of Seven Pseudomonas fluorescens Subclade III Strains Isolated from Cystic Fibrosis Patients.

Authors:  Brittan S Scales; John R Erb-Downward; Ian M Huffnagle; John J LiPuma; Gary B Huffnagle
Journal:  Genome Announc       Date:  2015-01-29

Review 7.  Systematic review and meta-analysis of nasal potential difference in hypoxia-induced lung injury.

Authors:  Zhenlei Su; Lili Zhu; Jing Wu; Runzhen Zhao; Hong-Long Ji
Journal:  Sci Rep       Date:  2016-08-04       Impact factor: 4.379

8.  Effects of inhaled hypertonic (7%) saline on lung function test in preschool children with cystic fibrosis: results of a crossover, randomized clinical trial.

Authors:  Raffaella Nenna; Fabio Midulla; Caterina Lambiase; Giovanna De Castro; Anna Maria Zicari; Luciana Indinnimeo; Giuseppe Cimino; Patrizia Troiani; Serena Quattrucci; Giancarlo Tancredi
Journal:  Ital J Pediatr       Date:  2017-07-15       Impact factor: 2.638

Review 9.  Inhaled Biologicals for the Treatment of Cystic Fibrosis.

Authors:  Valentina Sala; Alessandra Murabito; Alessandra Ghigo
Journal:  Recent Pat Inflamm Allergy Drug Discov       Date:  2019

Review 10.  Optimising inhaled mannitol for cystic fibrosis in an adult population.

Authors:  Patrick A Flume; Moira L Aitken; Diana Bilton; Penny Agent; Brett Charlton; Emma Forster; Howard G Fox; Helge Hebestreit; John Kolbe; Jonathan B Zuckerman; Brenda M Button
Journal:  Breathe (Sheff)       Date:  2015-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.